CRP and chronic obstructive pulmonary disease: The inhaled narrow spectrum kinase (p38α + Src family) inhibitor (JNJ49095397/RV568) in patients with moderate to severe COPD decreased serum CRP levels as well as improved trough FEV1 and dyspnoea index scores.246 However, p38αMAPK inhibitors block the upstream MAPK kinase kinases, leading to hyperactivation of the transforming growth factor-activated kinase-1 and mixed-lineage kinase which then hyperactivate the JNK.